On the afternoon of January 20, the review of annual events of biomedical industry and the signing of 2022 Shanghai international biomedical industry week were held in Shanghai.
The reporter learned from the signing site that the 2022 Shanghai international biomedical week will be held in Shanghai from September 26 to 30. Six units, including JPMorgan Chase, Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) , Shanghai Pharmaceuticals Holding Co.Ltd(601607) , Zhangjiang group, pharmaceutical information society and e Fangda, have signed up to become the first “strategic partners” of the industry week.
Biomedical industry is an important pillar of Shanghai’s strategic emerging industries, an important starting point for Shanghai to strengthen the leading function of high-end industries and the source function of scientific and technological innovation, and one of the three leading industries entrusted by the CPC Central Committee with the important mission of “building a world-class industrial cluster” in Shanghai.
According to the data, in 2021, the scale of Shanghai’s biomedical industry is expected to exceed 700 billion yuan. After reaching 600 billion yuan for the first time in 2020, the industrial scale has reached a new level, of which the output value of manufacturing industry is 171.2 billion yuan, a comparable increase of 12%.
At the signing ceremony, the white paper on the development of Shanghai biomedical industry was released.
According to the white paper, during the 13th Five Year Plan period, Shanghai’s biomedical industry showed a good development trend. The total industrial output value of manufacturing industry increased from 95.86 billion yuan to 141.661 billion yuan, with an average annual compound growth of 10.3%, and its proportion in Shanghai’s total industrial output value increased from 2.9% in 2016 to 4.1% in 2020.
Innovative achievements continue to emerge, and major breakthroughs have been made in the fields of synthetic biology, stem cell and regenerative medicine, brain science and neuroscience. A number of large scientific facilities and 17 national key laboratories have been built. A total of 14 Class 1 new drugs have been listed for the first time, including 8 NEW drugs listed by the license holder in Shanghai and 918 class 3 medical devices have been registered for the first time.
Leading and backbone enterprises grew rapidly. The total number of Pharmaceutical Industrial Enterprises above designated size increased from 284 to 409, of which enterprises with operating income of more than 100 million yuan increased from 150 to 228, and 35 enterprises were listed in the forefront of the country. The industrial carrying space continues to improve, forming a “1 + 5 + X” industrial layout, accelerating the agglomeration of various innovative elements to the industrial park, and realizing “more than 80% of the two” (more than 80% of biomedical investment projects are concentrated in the industrial park, and more than 80% of the output value of biomedical manufacturing industry is contributed by the Industrial Park).
The industrial ecology has been continuously optimized, and the “municipal hospital hospital enterprise collaborative research and innovation platform (hi-clip) – clinical trial accelerator” has been established and released for the first time; Shanghai has become the most active area of investment and financing in the field of medical and health care in China, and the equity investment fund of Shanghai biomedical industry has been established; Academicians in the field of biomedicine, Changjiang Scholars and other high-level talents account for 1 / 5 of the country, and industrial talents account for 1 / 4 of the country; The Yangtze River Delta sub center for drug evaluation and inspection and the Yangtze River Delta sub center for technical evaluation and inspection of medical devices of the State Drug Administration have settled in Shanghai.
